Results 171 to 180 of about 9,000,818 (348)
β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero +8 more
wiley +1 more source
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou +5 more
wiley +1 more source
Manual wheelchair training for individuals with chronic and progressive conditions: a critical realist approach to improving practice. [PDF]
Charlton K +3 more
europepmc +1 more source
Is Psychiatric Illness Leading Reason of Neonaticide in Lithuania?
Vaiva Martinkienė +1 more
openalex +1 more source
Age, gender, functional KSS, reason for revision and type of bone defect predict functional outcome 5 years after revision total knee arthroplasty: a multivariable prediction model [PDF]
Jan Verbeek +4 more
openalex +1 more source
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source
Dental Treatment Discontinuation for Financial Reasons Among Patients with Cancer: A Cross-Sectional Study with Non-Cancer Controls. [PDF]
Lee K.
europepmc +1 more source

